ABOUT CRIDO

CRIDO advised on the sale of 100 percent of Aura Medic Południe shares

5 April 2022
2 min

CRIDO acted as Corporate Finance advisors to the Owners of Aura Medic Południe sp. z o.o., which owns two magnetic resonance diagnostic centres – in Stalowa Wola and Radomsko.

Two magnetic resonance diagnostic centres (in Stalowa Wola and Radomsko) have come under new ownership. The previous owners chose to sell 100 percent of their shares in the company to Bonus-Diagnosta sp. z o.o., a company controlled by PZU Zdrowia S.A., which operates in the medical services sector.

The sale was facilitated by CRIDO, which acted as the sole corporate finance advisor to the company’s owners. Transactional advice was rendered by: Artur Marszałkiewicz, managing partner at CRIDO leading the Corporate Finance team, Aleksandra Małolepsza, senior associate, and Monika Olak, senior financial analyst.

Artur Marszałkiewicz and his CRIDO team supported us throughout the transaction. Thanks to the team’s professional handling of the process and their unwavering commitment we were able to negotiate very favourable terms – says Damian Biedulski, (former) President of the Board of Directors and Aura Medic shareholder.

We are pleased to have played our part in PZU Zdrowie’s dynamic growth in the medical services sector while securing very favourable commercial terms for our client – adds Artur Marszałkiewicz, managing partner heading CRIDO’s Corporate Finance team.

CRIDO supports entrepreneurs, corporations and PE/VC funds in domestic and cross-border M&A transactions at every stage in the process. CRIDO’s package of advisory services includes due diligence, tax, financial, corporate finance and comprehensive legal support, including legal due diligence.

CRIDO’s Corporate Finance team provides comprehensive transaction advice in M&A processes. We also support clients in seeking financing for acquisitions, development, investment projects and project finance deals. This is made possible by our close cooperation with banks, PE funds and specialist funds.